PHARMIG

What PHARMIG does

PHARMIG — Verband der pharmazeutischen Industrie Österreichs — is the voluntary trade association representing the Austrian pharmaceutical industry. Founded in 1954 and headquartered in Vienna, the association serves approximately 120 member companies that collectively cover an estimated 95% of the Austrian medication market. Its membership spans major multinational pharmaceutical firms (Boehringer Ingelheim, Roche, Novartis, Pfizer, Sanofi, Takeda, MSD, GSK, AbbVie, AstraZeneca, Amgen, Bayer), generics manufacturers (Sandoz), and Austrian-based mid-market companies (Richter Pharma, Daiichi Sankyo Austria, Fresenius Kabi Austria, Viatris Austria). PHARMIG is governed by a President and Vice Presidents drawn from member-company executives, with a permanent secretariat led by Secretary General Alexander Herzog.

PHARMIG's "products" are not physical goods but member services delivered through a federation of standing working committees covering regulatory affairs (Arzneimittelzulassung), drug supply security (Arzneimittelversorgung), pharmacovigilance, clinical research, rare diseases, plasma proteins, public affairs and market access, European and international affairs, patient advocacy, manufacturing and quality assurance, legal and compliance, communications, and health data and digital. It also operates the PHARMIG Academy for professional training, the Pharmajobs recruitment portal, the Pharmastandort Österreich investment-promotion platform, the AMVO anti-counterfeiting verification system, and recurring publications including PHARMIG Info and the annual Daten & Fakten statistical compendium. Member compliance is governed by the PHARMIG Verhaltenscodex.

The business model is subscription-recurring: voluntary membership fees from ~120 pharmaceutical companies, supplemented by academy/training fees, publication/event sponsorship, and event ticket revenue (including international events such as Pharmig India 2025). Go-to-market is sales-led via direct engagement with pharma executives. PHARMIG is registered as a Verein (non-profit association) under Austrian law, domiciled in Vienna, and is not a publicly traded entity; its "ownership" sits with the member companies participating in the General Assembly.

Name

PHARMIG

Legal name

PHARMIG - Verband der pharmazeutischen Industrie Österreichs

Website

https://pharmig.at

Company type

Private

Founded year

1954

Operating status

Operating

Headcount range

11–50 employees

Short description

PHARMIG is the voluntary Austrian pharmaceutical industry association, representing ~120 member companies covering roughly 95% of the country's medication market through advocacy, regulatory committees, training, and policy influence.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association

NAICS

Professional, Scientific, and Technical Services (541)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Access Policy, Advocacy & Stakeholder Management (HLAIAKAL)

akta.pro secondary industry

Signal Detection & Safety Analytics (Epidemiology/RWE) (HLAGALAC)

Keywords

• Pharmaceutical industry association
• Industry advocacy services
• Regulatory affairs consulting
• Pharmaceutical market access
• Professional training programs

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Membership Fees: PHARMIG generates revenue through voluntary membership fees from approximately 120 pharmaceutical companies operating in Austria. Membership provides access to industry representation, regulatory guidance, networking, training (PHARMIG Academy), and advocacy services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

PHARMIG is the voluntary interest representation of the Austrian pharmaceutical industry, providing policy advocacy, regulatory guidance, market access support, and member services through working committees covering drug supply, drug approval, clinical research, pharmacovigilance, rare diseases, plasma proteins, patient advocacy, manufacturing & quality, legal & compliance, communications, and health data & digital. The association also operates the PHARMIG Academy training and certificate programs, publishes the PHARMIG Info newsletter and annual Daten & Fakten report, maintains the PHARMIG Verhaltenscodex compliance framework, and runs the Pharmastandort Österreich investment portal and AMVO anti-counterfeiting verification system.

Product overview

PHARMIG is a voluntary trade association (Verband) representing the Austrian pharmaceutical industry with approximately 120 member companies covering about 95% of the Austrian medication market. Rather than offering a unified product platform, PHARMIG provides a comprehensive suite of services organized into working committees (Arbeitsbereiche) covering key industry domains: Arzneimittelversorgung (drug supply), Arzneimittelzulassung (regulatory affairs), Rare Diseases, Plasmaproteine (plasma proteins), Pharmakovigilanz (drug safety), Klinische Forschung (clinical research), Public Affairs und Market Access, European & International Affairs, Patient Advocacy, Herstellung & Qualitätssicherung (manufacturing & quality), Legal & Compliance, Communications, and Health Data & Digital. The association complements these member services with educational offerings through the PHARMIG Academy (certificate programs and continuing education), regular publications including PHARMIG Info newsletter and annual Facts & Figures (Daten & Fakten) reports, and specialized initiatives such as the Pharmastandort Österreich digital portal for investment promotion and the AMVO anti-counterfeiting verification system. The association also publishes patient-focused resources like the "Ihr Recht als Patient:in" guide and operates the PHARMIG Verhaltenscodex compliance framework.

Differentiator

Problem solved

Functional benefit

Products and services

• PHARMIG Academy Educational and training division of the association offering professional development courses, certificate programs (e.g., Zertifikatslehrgang Compliance schützt), and continuing education for the pharmaceutical and life sciences industry in Austria.
• PHARMIG Info (Newsletter) Regular newsletter publication covering industry news, policy updates, member company highlights, and health policy commentary from Generalsekretär Alexander Herzog.
• PHARMIG Daten & Fakten (Facts & Figures) Annual statistical publication providing data and background information on the Austrian pharmaceutical industry and healthcare system, including statistics on employment, investment, and market data.
• PHARMIG Verhaltenscodex (Code of Conduct) Compliance framework establishing ethical standards and behavioral guidelines for member companies in the Austrian pharmaceutical industry.
• Pharmastandort Österreich Digital platform showcasing Austria as a pharmaceutical industry location, highlighting investment opportunities, research strengths, and industry data (18,000 employees, 150 companies, investments in the millions).
• AMVO (Arzneimittelverifikation Österreich) EU Directive 2011/62-compliant online verification system for prescription medicines to secure against falsification in the Austrian pharmaceutical supply chain.
• Ihr Recht als Patient:in (Patient Rights Guide) Patient guide covering rights within the Austrian healthcare and social insurance system, from diagnosis through treatment and aftercare.

Quantifiable outcome

• 95% market coverage through 120 member companies
• +2 more outcomes

Named customers20 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core, minor and moderate.

• European Medicines Agency (EMA)coreOthersPHARMIG maintains working relationships with the European Medicines Agency on regulatory and market access matters affecting Austrian pharmaceutical companies. The association provides industry input on EMA policies and guidance.
• World Health Organization (WHO)minorOthersPHARMIG engages with WHO on global health policy matters including vaccination programs, medicine safety, and pandemic preparedness. The association supports WHO initiatives relevant to the pharmaceutical industry.
• European Federation of Pharmaceutical Industries and Associations (EFPIA)coreStrategic or Co-development PartnerPHARMIG represents Austrian pharmaceutical industry interests within the European pharmaceutical association network. Through EFPIA, PHARMIG participates in EU-wide policy discussions and industry coordination.
• Austrian Federal Ministry for Social Affairs, Health, Care and Consumer Protection (BMSGPK)coreOthersPHARMIG maintains ongoing dialogue with the Austrian health ministry on pharmaceutical policy including drug pricing, reimbursement, supply security, and regulatory matters affecting the Austrian pharmaceutical sector.
• Medical University of ViennamoderateStrategic or Co-development PartnerPHARMIG collaborates with academic institutions on clinical research, health economics, and innovation policy. The association participates in joint events and discussions on strengthening Austria as a pharmaceutical research location.
• Pharmig UKminorStrategic or Co-development PartnerPHARMIG collaborates with Pharmig UK on organizing events such as Pharmig India 2025, an Asia's largest microbiology summit on contamination control and sterilization practices, bringing together global experts.
• Pro Rare AustriamoderateGTM or Marketing PartnerPHARMIG Academy organizes Rare Diseases Dialog events in partnership with Pro Rare Austria, bringing together patient organizations, industry, and policymakers to discuss rare disease policy and patient access to therapies.
• Österreichische DatenschutzbehördeminorOthersPHARMIG complies with Austrian Data Protection Authority requirements and maintains data protection policies in accordance with DSGVO and Austrian data protection legislation.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Regional players

• LEEM (Les Entreprises du Médicament): French pharmaceutical industry association. Comparable as a national pharma trade body with advocacy, regulatory affairs, and member committee structures serving a major European market.
• Interpharma: Swiss pharmaceutical industry association representing research-based pharma in Switzerland. Directly comparable national trade body operating in the same DACH regulatory and policy environment as PHARMIG.
• Farmindustria: Italian pharmaceutical industry association. Peer in the European national pharma association network, offering comparable advocacy, working groups, and member services within Italy's national framework.
• ABPI (Association of the British Pharmaceutical Industry): UK pharmaceutical industry trade association. Comparable in mandate, member services, and policy advocacy function, though operating in a distinctly different national regulatory environment.

Broad incumbents

• IFPMA (International Federation of Pharmaceutical Manufacturers and Associations): Global pharmaceutical industry association. Comparable as the apex trade body structure in which PHARMIG and its national counterparts participate, representing the same advocacy and member-service model at a global scale.
• PhRMA (Pharmaceutical Research and Manufacturers of America): The largest national pharma industry association globally, representing US research-based pharma companies. Comparable in mandate and operating model but at a vastly larger scale and in a different regulatory jurisdiction.
• BIO (Biotechnology Innovation Organization): US-based biotech and biopharma trade association. Comparable as an industry advocacy body with member services spanning policy, market access, and education, though focused on the biotechnology segment.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): The pan-European pharma industry association of which PHARMIG is a national member. EFPIA operates at a broader EU-wide scope and represents the same category of trade association services, making it the closest structural peer.

Direct peers

• vfa (Verband forschender Arzneimittelhersteller): German association of research-based pharmaceutical companies. Comparable to PHARMIG in advocating for innovator pharma companies on policy, market access, and regulatory issues, with a similar committee-based service model.
• BPI (Bundesverband der Pharmazeutischen Industrie): Germany's national pharmaceutical industry association, directly comparable to PHARMIG in structure, mandate, and service portfolio (advocacy, market access, working committees) within the DACH region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmig

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PHARMIG